Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1501 + Adebrelimab in Advanced Malignancies
NCT03995472Phase 1Completed
- Sponsor
- Hengrui
- Start
- Feb 2020
- Primary completion
- Jan 2023
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of SHR-1501 in solid tumor (advanced stage) (3 arms), sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity at 42 days, Maximum Tolerated Dose at 42 days and 2 more. Started Feb 2020; status: completed.
02
Drugs
SHR-1501
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03995472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995472.